| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
DURHAM, NC – November 2, 2026 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 26, 2026. |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition; Other Events
DURHAM, NC – August 5, 2026 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 27, 2026. |
| 04 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Bioventus, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) on June 3, 2026. A total of 75,279,174 shares (the “Shares”) of both Class A common stock and Class B common stock (collectively, th... |
| 21 May 2026 |
8-K: Regulation FD Disclosure
On April 16, 2026, the U.S. Food and Drug Administration (“FDA”) issued a final order reclassifying non-invasive bone growth stimulators, including the Company’s Exogen® Ultrasound Bone Healing System, from Class III to Class II devices.... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
DURHAM, NC – May 6, 2026 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 28, 2026. |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
DURHAM, NC — March 5, 2026 — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2... |
| 17 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On November 14, 2025, the Board of Directors (the “Board”) of Bioventus Inc. (the “Company”) appointed Ajay Dhankhar, PhD, to the Board as a Class II director effective on November 14, 2025. Dr. Dhankhar will serve for a term ending at t... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
DURHAM, NC – November 4, 2025 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 27, 2025. |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
DURHAM, NC – August 6, 2025 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 28, 2025. |
| 04 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
WELLS FARGO SECURITIES, LLC, DNB MARKETS, INC., JPMORGAN CHASE BANK, N.A. |
| 31 Jul 2025 |
8-K: Other Events
DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances f... |
| 04 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Bioventus, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) on June 3, 2025. A total of 73,619,248 shares (the “Shares”) of both Class A common stock and Class B common stock (collectively, th... |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition
DURHAM, NC – May 6, 2025 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 29, 2025. |
| 11 Mar 2025 |
8-K: Results of Operations and Financial Condition
DURHAM, NC — March 11, 2025 — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, ... |
| 03 Jan 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Other Events
DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Adv... |
| 05 Nov 2024 |
8-K: Results of Operations and Financial Condition
DURHAM, NC – November 5, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, 2024. |
| 04 Oct 2024 |
8-K: Entry into a Material Definitive Agreement; Other Events
ANNEX I Balance Sheet Rules and Working Capital Illustrative Example |
| 06 Aug 2024 |
8-K: Results of Operations and Financial Condition
DURHAM, NC – August 6, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 29, 2024. |
| 19 Jul 2024 |
8-K: Other Events
As previously disclosed, on January 12, 2023, Bioventus Inc. (the “Company” or “Bioventus”) and certain of its current and former directors and officers were named as defendants in a putative class action lawsuit filed in the Middle Dist... |
| 21 Jun 2024 |
8-K: Entry into a Material Definitive Agreement
This Amendment No. 1 to Stockholders Agreement (this “Amendment”) is entered into as of June 19, 2024 by and among (i) Bioventus Inc., a Delaware corporation (the “Company”), (ii) Bioventus LLC, a Delaware limited liability company (“Bio... |
Loading...